In recent years, inhibitors targeting TGF-β pathway have been discovered and investigated by pharmaceutical companies for cancer therapy, and some of them are in clinical trial now, such as Phase I study of GC1008 (fresolimumab), Ph II study of NCT01453361 (Gemogenovatucel-T) and so on [58,59]. This evidence concerns the gene TGFB1 and cancer.